ArticleLeukemia2018
The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
Open access · hybridAbstract read
In one paragraph
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 88 citations in OpenAlex.
- Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment.JCI insight · 2023Trial
- KSHV-encoded vIRF3 cooperates with cellular IRF4 to drive super-enhancer activity through complex DNA elements.Nucleic acids research · 2026Article
- The Role of AP-1 in Cancer: Regulation, Tumor Microenvironment and Therapeutic Targeting.Biomolecules · 2026Review
- Continuous DNA methylation deconvolution-based surrogate for B-cell differentiation state in chronic lymphocytic leukemia.Communications medicine · 2026Article
- Genome-epigenome crosstalk in T-cell lymphomas: from maps to mechanisms.International journal of hematology · 2026Review
- The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.Leukemia · 2026Article
- Continuous DNA Methylation Deconvolution-Based Surrogate for B-Cell Differentiation State in CLL.bioRxiv : the preprint server for biology · 2025Article
- The AP-1 factor JUNB correlates with poor survival of patients with esophageal adenocarcinoma.Scientific reports · 2025Article
- Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.Cancer discovery · 2025Article
- Identification of a novel immune checkpoint-related gene signature predicts prognosis and immunotherapy in breast cancer and experiment verification.Scientific reports · 2024Article
- Review
- Punicalagin as a novel selective aryl hydrocarbon receptor (AhR) modulator upregulates AhR expression through the PDK1/p90RSK/AP-1 pathway to promote the anti-inflammatory response and bactericidal activity of macrophages.Cell communication and signaling : CCS · 2024Article
- BATF promotes tumor progression and association with FDG PET-derived parameters in colorectal cancer.Journal of translational medicine · 2024Article
- Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma.Cancer medicine · 2024Article
- Review
- STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma.Cell reports. Medicine · 2024Article
- Identification and validation of BATF as a prognostic biomarker and regulator of immune cell infiltration in acute myeloid leukemia.Frontiers in immunology · 2024Article
- CEMIG: prediction of the cis-regulatory motif using the de Bruijn graph from ATAC-seq.Briefings in bioinformatics · 2023Article
- TCR Pathway Mutations in Mature T Cell Lymphomas.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Transcriptional reprogramming by mutated IRF4 in lymphoma.Nature communications · 2023Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 12 institutions in 6 countries.
Nikolai SchleussnerMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Olaf MerkelInstitute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Mariantonia CostanzaMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.ORCID http://orcid.org/0000-0002-8959-1083
Huan-Chang LiangInstitute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Franziska HummelMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Chiara RomagnaniGerman Rheumatism Research Centre, German Rheumatism Research Centre (DRFZ), A Leibniz Institute, 10117, Berlin, Germany.
Pawel DurekGerman Rheumatism Research Centre, German Rheumatism Research Centre (DRFZ), A Leibniz Institute, 10117, Berlin, Germany.
Ioannis AnagnostopoulosInstitute of Pathology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany.
Michael HummelInstitute of Pathology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany.
Korinna JöhrensInstitute of Pathology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany.
Antonia NiedobitekMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Patrick R GriffinThe Scripps Research Institute, Jupiter, FL, 33458, USA.
Roberto PivaDepartment of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies, University of Torino, Torino, Italy.
Henrike L SczakielMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Wilhelm WoessmannEuropean Research Initiative on ALK-Related Malignancies (ERIA), Cambridge, UK.
Christine Damm-WelkEuropean Research Initiative on ALK-Related Malignancies (ERIA), Cambridge, UK.
Christian HinzeMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Dagmar StoiberInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Vienna, Austria.
Bernd GillissenHematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 12200, Berlin, Germany.
Suzanne D TurnerEuropean Research Initiative on ALK-Related Malignancies (ERIA), Cambridge, UK.
Eva KaergelMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Linda von HoffMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Michael GrauDepartment of Medicine A, Albert-Schweitzer-Campus 1, University Hospital Münster, 48149, Münster, Germany.
Georg LenzDepartment of Medicine A, Albert-Schweitzer-Campus 1, University Hospital Münster, 48149, Münster, Germany.
Bernd DörkenMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Claus ScheidereitMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Lukas KennerInstitute of Clinical Pathology, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.
Martin JanzMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Stephan MathasMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany. stephan.mathas@charite.de.
Max Delbrück Center · DECharité - Universitätsmedizin Berlin · DEGerman Cancer Research Center · DEBlackberry (United States) · USGerman Rheumatism Research Centre · DEJustus-Liebig-Universität Gießen · DEMedical University of Vienna · ATInnovative Medicines Initiative · BELudwig Boltzmann Institute for Cancer Research · ATScripps Research Institute · USUniversity of Cambridge · GBUniversity of Turin · IT
Funding
Austrian Science Fund FWF P 26011
Abstract
Transcription factor AP-1 is constitutively activated and IRF4 drives growth and survival in ALK
Indexed as
Basic-Leucine Zipper Transcription FactorsBinding SitesCarrier ProteinsCell DeathCell Line, TumorCell SurvivalCRISPR-Cas SystemsCytokinesGene EditingGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansLymphoma, Large-Cell, AnaplasticProtein BindingProtein Kinase InhibitorsRNA, Small InterferingBasic-Leucine Zipper Transcription FactorsBATF protein, humanCarrier ProteinsCytokinesProtein Kinase InhibitorsRNA, Small InterferingTranscription Factor AP-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.